Defects in the expression and/or function of the human leukocyte antigen (HLA) class I antigen-processing machinery (APM) components are found in many tumor types. These abnormalities may have a negative impact on the interactions of tumor cells with host's immune system and on the outcome of T cell-based immunotherapy. To the best of our knowledge, no information is available about APM component expression and functional characteristics in human medulloblastoma cells (Mb). Therefore, in the present study, we have initially compared the expression of APM components in Mb, an embryonal pediatric brain tumor with a poor prognosis, with that in noninfiltrating astrocytic pediatric tumors, a group of differentiated brain malignancies with favorable prognosis. LMP2, LMP7, calnexin, B2-microglobulin-free heavy chain (HC) and B2-microglobulin were down-regulated or undetectable in Mb lesions, but not in astrocytic tumors or normal fetal cerebellum. Two Mb cell lines (DAOI and D283) displayed similar but not superimposable defects in APM component expression as compared with primary tumors. To assess the functional implications of HLA class I APM component downregulation in Mb cell lines, we tested their recognition by HLA class I antigen-restricted, tumor antigen (TA)-specific CTL, generated by stimulations with dendritic cells that had been transfected with Mb mRNA. The Mb cell lines were lysed by TA-specific CTL in a HLA-restricted manner. Thus, defective expression of HLA class I-related APM components in Mb cells does not impair their ability to present TA to TA-specific CTL. In conclusion, these results can contribute to optimize T cell-based immunotherapeutic strategies for Mb treatment.
Introduction
Recognition of tumor cells by human leukocyte antigen (HLA) class I antigen-restricted, tumor antigen (TA)-specific CTLs is mediated by h2-microglobulin-associated HLA class I heavy chains (HC) loaded with TA-derived peptides. A crucial role in the generation of these complexes is played by the HLA class I antigenprocessing machinery (APM) through three major steps (1): (a) the constitutive proteasome subunits MB-1, delta, and zeta and, more efficiently, the immunoproteasome subunits LMP2, LMP7, and LMP10 cleave mostly, although not exclusively, proteins into 8 to 10 amino acid peptides (2); (b) peptides are transported by ATPdependent peptide transporter (TAP) to endoplasmic reticulum (3); and (c) peptides are loaded onto nascent HLA class I molecules with the help of the chaperons calnexin, calreticulin, ERp57, and tapasin (4, 5) .
It has been known for some time that the malignant transformation of cells may be associated with abnormalities in the expression and/or function of HLA class I APM components and/or HLA class I subunits, which may cause defects in the cell surface expression of HLA class I HC-h2-microglobulin-peptide complexes (6) . Such abnormalities are found in many tumor types and preclude recognition of tumor cells by CTL (6) . Suggestive, but not conclusive, evidence implies that abnormalities in APM component expression in malignant lesions have a negative impact on the clinical course of the underlying disease because they may be associated with reduced disease-free interval and/or survival (7) (8) (9) .
Medulloblastoma (Mb) is a malignant, neuroepithelial embryonal tumor of the cerebellum with predominant neuronal differentiation and tendency to metastasize via cerebrospinal fluid pathways (10) . Mb includes several histopathologic subtypes, all of which correspond to WHO grade IV (10) (11) (12) . The most common subtype is the classic Mb (10) . The prognosis of Mb is still grim in a significant proportion of patients (10) , and novel therapeutic strategies are needed. To the best of our knowledge, no information is available about the expression of HLA class I APM component expression and function in Mb lesions. Because this information may contribute to a better understanding of the role of immunologic mechanisms in the clinical course of Mb and to the optimization of immunotherapeutic strategies for its treatment, we have here investigated (a) the expression of HLA class I-related APM components in Mb primary tumors and cell lines, in comparison with noninfiltrating astrocytomas as a model of welldifferentiated, pediatric brain tumors and (b) the functional relevance of APM component down-regulation in medulloblastoma cells.
Materials and Methods
Patients. A total of 10 primary classic Mb and 11 primary noninfiltrating astrocytoma lesions, resected at disease onset, were retrieved from the files of the Department of Neurosurgery at the Giannina Gaslini Institute (IGG), Genoa, Italy. The noninfiltrating astrocytoma lesions that included eight pilocytic atrocytomas (PA), two pleomorphic xantoastrocytomas (PXA), and one subependimal giant cell astrocytoma (SEGA), will be referred to as ''astrocytic tumors.'' The main Mb patient characteristics, including age, gender, anatomic site, and stage of the tumors, are summarized in Table 1 . The age of patients with astrocytic tumors ranged from 2 to 11 months; nine of them were males, and two were females. All patients underwent surgery before any other therapy. No patient was immunocompromised; all were HIV negative. Tissue sections from a human fetal brain (gestational age: 28 weeks) were stained with APM component-specific monoclonal antibody (mAb) as normal counterpart.
Histopathologic diagnoses were made by routine light microscopic evaluation of formalin-fixed, paraffin-embedded tissue sections stained with H&E and silver impregnation for reticulin. Immunohistochemical stainings for synaptophysin, vimentin, neuron-specific enolase, glial fibrillary acid protein, S-100 protein, epithelial membrane antigen, CD34, and Mib-1 were also done for diagnostic purposes (10, 13) .
Cell lines. The Mb cell lines, DAOI and D283, and the Raji Burkitt lymphoma cell line were maintained in RPMI 1640 (Euroclone) supplemented with 10% fetal bovine serum (FBS, Life Technologies Invitrogen), HEPES buffer, nonessential amino acids, L-glutamine and penicillin/ streptomycin (Cambrex Bio Science Verviers). Before being used as targets in ELISPOT and cytotoxicity assays, the DAOI and D283 cell lines were cultured for 48 h in the presence human rIFN-g (Boehringer Ingelheim Italia) at the final concentration of 1,000 IU/mL that, in previous experiments, proved to be optimal for HLA-ABC up-regulation on neuroblastoma cell lines (14) .
Antibodies. The mAb HC 10, which recognizes a determinant expressed on all h2-microglobulin-free HLA-B HCs and on h2-microglobulin-free HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, and HLA-A33 HC (15, 16) ; the anti-h2-microglobulin-specific mAb L368 (17) and the mAb TP25.99, which recognizes a conformational determinant expressed on all h2-microglobulin-associated HLA-ABC HC and a linear determinant expressed on all h2-microglobulin-free HLA-B HC except HLA-B73 and on h2-microglobulin-free HLA-A1, HLA-A3, HLA-A9, HLA-A11, and HLA-A30 HC were developed and characterized as described (18) . The MB-1-mAb SY-1, the LMP7-specific mAb SY-3, the LMP10-specific mAb TO-7, the TAP2-specific mAb NOB-2, the calnexin-specific mAb TO-5, the calreticulinspecific mAb TO-11, the ERp57-specific mAb TO-2, and the tapasin-specific mAb TO-3 were developed and characterized as described elsewhere (19, 20) . With the exception of mAb HC10 which is an immunoglobulin G 2a (IgG 2a ), all the other mAbs are of the IgG 1 isotype. IgG 1 and IgG 2a irrelevant mAb, which were used as negative controls, were purchased from Southern Biotechnology Associates. CD40-PE was purchased from Diaclone Research. CD80-FITC and CD86-PE were purchased from BD PharMingen. Isotypematched IgG 2b -PE, IgG 1 -FITC, and IgG 1 -PE, used as negative controls, were purchased from Caltag.
All APM component-specific mAb were preliminarily titrated using the Raji Burkitt lymphoma cell line as reported (14) .
Immunohistochemical staining of tissues with mAb. Immunohistochemical staining of tissue sections with mAb was done using the Envision System HRP mouse (DAKO) following the procedure described elsewhere (14) . In brief, formalin-fixed, paraffin-embedded tissue sections were incubated first for 40 min at 98jC in citrate solution for antigen retrieval and subsequently overnight at 4jC with optimal amounts of mAb. The latter was selected by titrating each mAb preparation with human tonsil tissue sections in preliminary experiments.
Tissue sections were washed twice in Optimax wash buffer and incubated for 30 min at room temperature with DAKO Envision System HRP mouse. After washing in Optimax wash buffer, peroxidase activity was detected by incubating tissue sections for 6 to 10 min at room temperature with DAKO Liquid DAB Substrate Chromogen System. Tissue sections were counterstained with Mayer's hematoxylin (Sigma). Table 2 . HLA class I antigen-processing molecule expression in primary pediatric medulloblastoma
Patients HLA-ABC Heavy chain h2-Microglobulin Tapasin Calnexin Calreticulin Erp57 LMP2 LMP7 LMP10 MB-1 Zeta Delta TAP2
The percentage of stained tumor cells in each lesion was evaluated independently by two investigators. The variation between the results obtained by the two investigators was <10%. Results were scored as negative, heterogeneous, and positive, when the percentage of stained tumor cells in each microscopic area was <25%, between 25% and 75%, and more than 75%, respectively (7). The assignment of each tumor sample to one of the above scores was based on the score of the microscopic area containing the highest number of stained tumor cells. Flow-cytometric analysis of cell lines. The intracellular staining of cell lines with mAb was done as described (21) . Briefly, cells were fixed with 2% paraformaldehyde at room temperature for 20 min, washed, and resuspended at 5 Â 10 5 /mL in PBS containing 0.5% FBS for microwave treatment at 200 W power for 45 s. Cells were then chilled on ice for 10 min, washed twice with staining buffer, and incubated in permeabilization buffer (PBS, 1% FBS, 0.1% saponin; Sigma) at room temperature for 30 min. Cells (5 Â 10 5 per tube) were next incubated with the primary mAb at room temperature for 30 min, washed twice with permeabilization buffer, and incubated with FITC-conjugated F(ab') 2 fragments of rabbit anti-mouse IgG antibodies at room temperature for 30 min. Cells were finally washed twice in permeabilization buffer and resuspended in staining buffer before being analyzed by flow cytometry using a FACScan instrument (BD Biosciences).
For surface staining, cells were sequentially incubated with an optimal amount of primary mAb and with an optimal amount of FITC-conjugated F(ab') 2 fragments of rabbit anti-mouse Ig antibodies. Stained cells were analyzed by flow cytometry. Isotype-and subclass-matched mouse Ig were used as negative controls in all the experiments. Cell Quest software (BD Biosciences) was used for data analysis. The results of flow cytometry experiments are expressed as mean relative fluorescence intensity (MRFI), i.e., the ratio between the mean fluorescence intensity (MFI) of cells stained with the selected mAb and the MFI of cells stained with isotype-matched mouse Ig.
Mb cell mRNA extraction and DC transfection. mRNA was extracted from DAOI and D283 Mb cell lines using the mRNA Isolation Kit (Roche Diagnostics) according to the manufacturer's protocol and stored at À80jC until use. DC were generated from peripheral blood monocytes as described (22) . DC transfection was done using a nonlipid cationic reagent (Transmessenger Transfection Reagent; Qiagen) as described (22) . Mature DC were collected, washed twice in PBS (Sigma), and resuspended in X-VIVO medium. DC (1 Â 10 6 /500 AL) were then added to the transfection mixture. Following 45 min incubation at 37jC, DC were washed twice in PBS, resuspended in the maturation cocktail, and cultured for an additional 24 h before being used.
CTL generation. CD8 + T-cell suspensions were purified (>90% purity) from peripheral blood mononuclear cells (PBMC) of normal donors by immunomagnetic enrichment with CD8 MicroBeads (Miltenyi Biotec GmbH). CD8 + T cells (70,000 cells per well) were cultured in 96-well plates (Corning Incorporated) at a 10:1 ratio with autologous transfected DC in RPMI 1640 supplemented with 10% heat-inactivated human AB serum and 5 ng/mL rIL-7 (Peprotech EC). Lymphocytes underwent four rounds of weekly stimulation with autologous transfected DC; starting from the third round of stimulation, 20 ng/mL rIL-15 (Immunotools) were added to the culture medium. Immunophenotypic and functional characterization of CTL was done 7 days after the fourth round of stimulation. CTL phenotype was studied by single or double staining with CD3-FITC (BD PharMingen), CD8-PE (BD Biosciences), CD4-PE (BD Biosciences), anti-TCR-a/h-PE (BD PharMingen), CD16-FITC (BD PharMingen) mAbs followed by fluorescenceactivated cell sorting analysis. Isotype-matched mouse Ig (Caltag) were used as a negative control. Results are expressed as percentage of stained cells.
ELISPOT assays. ELISPOT assays for IFN-g was carried out using MAIPS4510 Multiscreen-IP Millipore plates coated overnight at 4jC with anti-IFN-g mAb (clone 1-DK-1, 1 Ag/mL; Mabtech). Plates were then washed and blocked with PBS 2% human albumin (Kedrion SpA
Cytotoxicity assays. Cytolytic activity of CTL was assessed against HLAmatched Mb cell line as target by a standard 4-h 51 Cr release assay. Effectorto-target (E/T) cell ratio ranged from 100:1 to 1:1. A 10-fold excess of unlabeled K562 cells was added to minimize natural killer (NK)-like activity. Blocking experiments were done by incubating target cells with 10 Ag/mL anti-HLA class I TP25.99 mAb for 30 min at room temperature before culture with lymphocytes. Specific lysis was determined using the formula % specific lysis = counts per minute (sample À spontaneous)/counts per minute (total À spontaneous) Â 100.
Statistical analysis. The m 2 test was used to compare data from immunohistochemical staining experiments. The Student's t test was used to analyze the data obtained from flow cytometry and cytotoxicity experiments.
Results
HLA class I APM component expression in pediatric Mb tumors. Table 2 summarizes the results obtained by immunoperoxidase staining of 10 primary pediatric Mb lesions with the panel of APM component-specific mAb. Microscopic areas containing more than 90% tumor cells were selected for the assessment of APM component expression. The delta, MB-1, and zeta housekeeping proteasomal subunits, the LMP10 immunoproteasomal subunit, the ATP-dependent peptide transporter TAP2, and the chaperone molecule ERp57 were detected in the majority of the Mb ( Fig. 1A ; Tables 2 and 3) , as well as astrocytic tumor (Tables 2  and 3 ), lesions.
Comparison of calnexin, calreticulin, and tapasin expression in Mb and astrocytic tumors showed that only calnexin had a significantly lower expression in the former than in the latter tumors (m 2 test, P = 0.001; Fig. 1B ; Tables 2 and 3 ). The immunoproteasomal subunits LMP2 and LMP7, h2-microglobulin-free HC, and h2-microglobulin were not detected in any of the Mb lesion tested, but were intensely expressed in astrocytic tumors ( Fig. 1C ; Tables 2 and 3) .
Finally, HLA-ABC molecules were not detected either in Mb or astrocytic tumors (Tables 2 and 3 ). Endothelial cells in each tissue section were stained by all the mAb tested, thus serving as positive internal controls (data not shown).
APM component expression in a normal fetal cerebellum. To define the APM component expression profile in a postulated 
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Cancer Res 2007; 67: (11 Figure 2A -D shows the staining patterns of the cerebellar cortex (composed of four layers, external granular, molecular, middle Purkinje, and internal granular) obtained with mAb recognizing HLA-ABC, h2-microglobulin-free HC, h2-microglobulin, tapasin, calnexin, calreticulin chaperons, MB-1, delta, zeta housekeeping proteasomal subunits, LMP2, LMP7, LMP10 immunoproteasomal components, ERp57 thiol-reductase, and TAP2 subunit. The staining intensity of most cerebellar cortex cells was strong for calnexin ( Fig. 2B-b) , calreticulin ( Fig. 2B-c) , MB-1 ( Fig. 2C-a) , delta ( Fig. 2C-b) , zeta ( Fig. 2C-c) , LMP2 ( Fig. 2C-d) , LMP7 (Fig. 2C-e) , ERp57 ( Fig. 2D-a) , TAP2 (Fig. 2D-b) . h2-microglobulin-free HC ( Fig. 2A-b) , tapasin ( Fig. 2B-a) , and LMP10 ( Fig. 2C-f ) were expressed with variable intensity only in some Purkinje cells.
Surface HLA-ABC ( Fig. 2A-a) and h2-microglobulin ( Fig. 2A-c ) were not detected in any cerebellar cortex cell. In contrast, endothelial cells were consistently stained by anti-HLA-ABC surface ( Fig. 2A-c) , and h2-microglobulin (Fig. 2 inset A-c) mAb.
These results suggest that the absence of h2-microglobulin-free HC, tapasin, calnexin, calreticulin, LMP2, LMP7, and TAP2 in Mb lesions are related to malignant transformation.
Expression of HLA class I-related APM components in Mb cell lines. APM component expression was next investigated in the human Mb cell lines DAOI and D283, differing in cell surface expression of HLA-ABC molecules, that are detected in DAOI, but not D283 cells. Figure 3A shows the mean F SE of the MRFI values obtained by cytofluorometric analysis of DAOI and D283 Mb cells stained with APM component-specific mAb.
Delta, calnexin, calreticulin, TAP2, h2-microglobulin-free HC, and h2-microglobulin were expressed in DAOI cells, with MRFI values ranging from 2.5 to 16 (Fig. 3A) . MB-1, zeta, LMP2, LMP7, LMP10, tapasin, and ERp57 expression was low to virtually undetectable, with MRFI values ranging from 1 to 2.5 (Fig. 3A) . Similar results were obtained from the analysis of the D283 Mb cell line with the exception of h2-microglobulin-free HC, h2-microglobulin, zeta, and TAP2 in which expression was low to undetectable (MRFI values ranging from 1 to 2.5; Fig. 3A) .
To determine whether the expression of APM components in the two Mb cell lines was modulated by IFNg, cells were incubated with IFNg (1,000 IU/mL) for 48 h at 37jC (14) . In DAOI cells, upregulation of h2-microglobulin-free HC, h2-microglobulin, zeta, TAP2, and surface HLA-ABC molecules was consistently detected (Fig. 3A) .
IFNg-treated D283 cells did not show up-regulation of any APM component, with the exception of calnexin (Fig. 3A) . In addition, de novo induction of surface HLA class I expression was observed in the same cells (Fig. 3A) .
Finally, DAOI and D283 cells tested negative for CD40, CD80, and CD86 costimulatory molecules (data not shown).
Antigen-presenting cell functions of Mb cell lines. CD8 + T-cell populations were purified from PBMC of normal donors. For CTL priming, CD8 + lymphocytes underwent four weekly cycles of stimulation with autologous DC transfected with pooled DAOI and D283 Mb cell line mRNA and were then expanded in medium containing human rIL-15 before being characterized.
The ability of in vitro expanded CTL to recognize DAOI and D283 cells was investigated by IFNg ELISPOT and 51 Cr release cytotoxic assays using IFNg-treated or untreated Mb cell lines as targets. Figure 3B shows that CD8 + T cells from an HLA-A2 + normal subject contained tumor-specific T cells secreting IFNg in response to HLA-matched DAOI and D283 cells. The frequency of specific spots in the CTL populations shown in Fig. 3B ranged from 58 to 60 IFNg spots per 30,000 blasts against DAOI cell line, 50 to 53 IFNg spots per 30,000 blasts against D283 cell line, 89 to 93 IFNg spots per 30,000 blasts against IFNg-treated DAOI cell line, and 67 to 70 IFNg spots per 30,000 blasts against IFNg-treated D283 cell line. IFNg secretion by CTL was significantly down-regulated when target cells were preincubated with HLA class I antigen-specific mAb (TP25.99), but not with an isotype-matched irrelevant mAb, before being tested in the ELISPOT assay (Fig. 3B) .
CTL lysed HLA-matched IFNg-treated or untreated DAOI Mb cells at different E/T ratios (Fig. 2C) . As expected, pretreatment of DAOI cell line with IFNg enhanced the specific lysis of target cells, especially at low E/T ratios ( from 25:1 to 3:1; Fig. 3C ). Cell lysis was significantly reduced by the addition of HLA class I-specific mAb, but not of an isotype-matched irrelevant mAb (Fig. 3D) . Likewise, D283 cells were lysed by Mb-specific CTL only after IFNg treatment, but with lower efficiency (data not shown).
Taken together, these results indicate that Mb-reactive CTL can be generated in vitro from normal subjects upon incubation with autologous DC transfected with tumor cell-derived mRNA. Tumor cell recognition by CTL implies that endogenous tumor-associated antigen (TAA)-derived peptides are presented as HLA class I antigen-peptide complexes on Mb cell surface.
Discussion
This is the first report on the expression of HLA class I-related APM in pediatric Mb. Abnormalities of APM component expression have been described in many malignant tumor cells such as melanoma, ovarian carcinoma, squamous head and neck carcinoma, and in three embryonal tumors, i.e., neuroblastoma, embryonal carcinoma, and invasive retinoblastoma (3, 7-9, 14, 23) .
Here, we show that multiple defects in the expression of HLA class I-related APM components are present in an embryonal malignancy of the central nervous system (CNS), i.e., pediatric Mb, but not in pediatric noninfiltrating astrocytic tumors, tested as a model of well-differentiated CNS neoplasia. Thus, the LMP2 and LMP7 immunoproteasomal components, the calnexin chaperon, h2-microglobulinfree HC, and h2-microglobulin were down-regulated or undetectable Table 3 . Expression of HLA class I antigen-processing molecules in pediatric Mb versus noninfiltrating astrocytic tumors
in Mb lesions, but were consistently expressed in astrocytic tumors. The latter finding has been already described in adult astrocytoma lesions, where HLA class I antigen down-regulation only correlated significantly with tumor grade (24) . In other tumor models, defects of APM components expression have been correlated to tumor progression and/or clinical course (7-9, 25, 26) The differences in the expression of HLA class I APM components in Mb versus astrocytic tumors reported in the present study may be attributable to the highly immature stage of differentiation of the former tumor. APM component expression was also investigated in normal fetal cerebellum, from which Mb is supposed to originate. These experiments showed that all APM components, but not HLA class I molecules, were expressed in fetal cerebellum, supporting the conclusion that the down-regulation of LMP2, LMP7, calnexin, h2-microglobulin-free HC, and h2-microglobulin in Mb lesions is associated with malignant transformation. Notably, in this respect, neurons and, to a lower extent, white matter astrocytes from normal mice were found to express LMP2 and LMP7 (27) .
Staining of the DAOI and D283 Mb cell lines with APM component-specific mAb revealed some differences in comparison with Mb primary tumors. In particular, MB-1, LMP10, and ERp57 were detected in the latter tumors but not in cell lines. In addition, DAOI, but not D283 cells, expressed h2-microglobulin, h2-microglobulin-free HC, and surface HLA-ABC molecules that were never detected in primary tumor cells. These differences may be related to the selection of tumor subclones during the establishment of neuroblastoma cell lines and/or to changes in the antigenic profile caused by long-term culture. An alternative possibility is that immunohistochemical analysis done with primary tumors was less sensitive than flow cytometry and, therefore, unable to detect, for example, low-level HLA class I expression.
The poor prognosis of Mb patients has fostered the search for novel therapeutic approaches, among which immunotherapy + T cell blasts derived from an HLA-A2 + healthy donor were tested for IFNg release by ELISPOT assays. T cells were cultured with medium alone (medium) or with HLA-matched DAOI Mb cell line, pretreated or not with IFNg (1,000 units/mL) at a 1:2 cell ratio. Experiments were done in the absence or in the presence of anti-HLA class I mAb. Indicated spot numbers per seeded lymphocytes represent mean values of three replicates FSD. P = 0.001 as assessed by Student's t test. C, CTL were tested for cytotoxic activity in 4-h 51 Cr release assays against HLA-matched Mb cell line. Results are expressed as percent of specific lysis at different E/T ratios. One representative experiment out of three done for each subject is shown. D, CTL were tested for cytotoxic activity in 4-h 51 Cr release assays against HLA-matched Mb cell line in the absence or in the presence of anti-HLA class I mAb. Results are expressed as percent specific lysis at 25:1 E/T ratio. Numbers represent the mean values of three replicates FSD. P = 0.01 and 0.02, respectively, as assessed by Student's t test.
has raised interest. Here, we investigated the role of DC, transfected with Mb-derived mRNA, in generating Mb-specific CTL. This strategy has been described in metastatic prostate carcinoma and neuroblastoma, in which tumor mRNA-transfected DC were found to stimulate TAA-specific CTL responses (22, 28) .
Mb mRNA-transfected DC promoted the in vitro expansion of CTL that released IFNg upon incubation with either Mb cell line and, most importantly, lysed the same cells in an HLA class Irestricted manner. Notably, inhibition of cytotoxicity by anti-HLA class I mAb, although significant, was less effective that that of IFN-g release. This difference is likely related to intrinsic features of the two assays, but the possibility that CTL-mediated NK-like activity had a minor role in tumor cell killing cannot be completely excluded.
Our results show that surface HLA class I molecules on Mb cell lines are functional, and that the latter cells can behave as APC, presenting endogenous HLA class I-restricted peptides derived from TAA to CTL.
These findings suggest that the numerous defects in the expression of HLA class I-related APM components, detected in Mb cell lines, do not affect the generation and expression of HLA class I-peptide complexes on the cell surface required for the recognition of target cells by CTL (6) .
Alternatively, as yet, poorly elucidated pathways of antigen processing and peptide generation may allow intracellular trafficking and surface expression of immunogenic HLA class Ipeptide complexes. The latter possibility is supported by the results of other studies (29, 30) in which TAP-independent mechanisms of peptide loading on HLA class I molecules and presentation of peptide/HLA class I complexes to T cells have been characterized. In summary, this study provides the first description of HLA class I-related APM component defects in pediatric Mb, leading to the unexpected conclusion that Mb cells can present tumorassociated antigens to CTL. These findings may pave the way to future development of T cell immunotherapy of Mb using autologous tumor-specific CTL.
